Graham Capital Management L.P. Takes $4.25 Million Position in Ralliant Corporation $RAL

Graham Capital Management L.P. purchased a new stake in Ralliant Corporation (NYSE:RAL) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 83,512 shares of the company’s stock, valued at approximately $4,252,000. Graham Capital Management L.P. owned 0.07% of Ralliant as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of RAL. Danske Bank A S bought a new stake in Ralliant in the 4th quarter valued at about $25,000. V Square Quantitative Management LLC bought a new stake in Ralliant in the 4th quarter valued at about $26,000. Allworth Financial LP lifted its position in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. Palisade Asset Management LLC bought a new stake in Ralliant in the 3rd quarter valued at about $26,000. Finally, BOKF NA bought a new stake in Ralliant in the 3rd quarter valued at about $29,000.

Analyst Ratings Changes

Several brokerages recently weighed in on RAL. Truist Financial reiterated a “buy” rating and issued a $68.00 price objective (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Zacks Research upgraded shares of Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Barclays lifted their price objective on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada lifted their price objective on shares of Ralliant from $47.00 to $64.00 and gave the company a “sector perform” rating in a research report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $67.30.

Ralliant Stock Down 0.0%

RAL stock opened at $68.76 on Wednesday. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $69.93. The company has a market capitalization of $7.70 billion and a price-to-earnings ratio of -6.28. The firm’s 50-day moving average is $54.11 and its two-hundred day moving average is $50.13. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company had revenue of $534.60 million for the quarter. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, analysts forecast that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s payout ratio is -1.83%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.